Literature DB >> 26876165

Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins.

Megan R Edwards1, Gai Liu2, Chad E Mire3, Suhas Sureshchandra4, Priya Luthra5, Benjamin Yen5, Reed S Shabman6, Daisy W Leung2, Ilhem Messaoudi4, Thomas W Geisbert3, Gaya K Amarasinghe7, Christopher F Basler8.   

Abstract

Suppression of innate immune responses during filoviral infection contributes to disease severity. Ebola (EBOV) and Marburg (MARV) viruses each encode a VP35 protein that suppresses RIG-I-like receptor signaling and interferon-α/β (IFN-α/β) production by several mechanisms, including direct binding to double stranded RNA (dsRNA). Here, we demonstrate that in cell culture, MARV infection results in a greater upregulation of IFN responses as compared to EBOV infection. This correlates with differences in the efficiencies by which EBOV and MARV VP35s antagonize RIG-I signaling. Furthermore, structural and biochemical studies suggest that differential recognition of RNA elements by the respective VP35 C-terminal IFN inhibitory domain (IID) rather than affinity for RNA by the respective VP35s is critical for this observation. Our studies reveal functional differences in EBOV versus MARV VP35 RNA binding that result in unexpected differences in the host response to deadly viral pathogens.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  RIG-I like receptor; VP35; filovirus; immune evasion; pattern associated molecular pattern (PAMP); type I interferon

Mesh:

Substances:

Year:  2016        PMID: 26876165      PMCID: PMC4767585          DOI: 10.1016/j.celrep.2016.01.049

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  36 in total

1.  Ebolavirus VP35 is a multifunctional virulence factor.

Authors:  Daisy W Leung; Kathleen C Prins; Christopher F Basler; Gaya K Amarasinghe
Journal:  Virulence       Date:  2010-11-01       Impact factor: 5.882

2.  Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression.

Authors:  Christopher R Kimberlin; Zachary A Bornholdt; Sheng Li; Virgil L Woods; Ian J MacRae; Erica Ollmann Saphire
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

3.  Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling.

Authors:  Mathieu Mateo; St Patrick Reid; Lawrence W Leung; Christopher F Basler; Viktor E Volchkov
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

4.  Marburg virus VP40 antagonizes interferon signaling in a species-specific manner.

Authors:  Charalampos Valmas; Christopher F Basler
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

5.  Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35.

Authors:  Daisy W Leung; Kathleen C Prins; Dominika M Borek; Mina Farahbakhsh; JoAnn M Tufariello; Parameshwaran Ramanan; Jay C Nix; Luke A Helgeson; Zbyszek Otwinowski; Richard B Honzatko; Christopher F Basler; Gaya K Amarasinghe
Journal:  Nat Struct Mol Biol       Date:  2010-01-17       Impact factor: 15.369

6.  BEDTools: a flexible suite of utilities for comparing genomic features.

Authors:  Aaron R Quinlan; Ira M Hall
Journal:  Bioinformatics       Date:  2010-01-28       Impact factor: 6.937

7.  Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs.

Authors:  Kathleen C Prins; Sebastien Delpeut; Daisy W Leung; Olivier Reynard; Valentina A Volchkova; St Patrick Reid; Parameshwaran Ramanan; Washington B Cárdenas; Gaya K Amarasinghe; Viktor E Volchkov; Christopher F Basler
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

8.  Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus.

Authors:  Amy L Hartman; Brian H Bird; Jonathan S Towner; Zoi-Anna Antoniadou; Sherif R Zaki; Stuart T Nichol
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

9.  Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1.

Authors:  Kathleen C Prins; Washington B Cárdenas; Christopher F Basler
Journal:  J Virol       Date:  2009-01-19       Impact factor: 5.103

10.  Marburg virus evades interferon responses by a mechanism distinct from ebola virus.

Authors:  Charalampos Valmas; Melanie N Grosch; Michael Schümann; Judith Olejnik; Osvaldo Martinez; Sonja M Best; Verena Krähling; Christopher F Basler; Elke Mühlberger
Journal:  PLoS Pathog       Date:  2010-01-15       Impact factor: 6.823

View more
  41 in total

1.  A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus Challenge.

Authors:  Courtney Woolsey; Andrea R Menicucci; Robert W Cross; Priya Luthra; Krystle N Agans; Viktoriya Borisevich; Joan B Geisbert; Chad E Mire; Karla A Fenton; Allen Jankeel; Sneha Anand; Hideki Ebihara; Thomas W Geisbert; Ilhem Messaoudi; Christopher F Basler
Journal:  Cell Rep       Date:  2019-09-17       Impact factor: 9.423

Review 2.  Molecular Mechanisms of Innate Immune Inhibition by Non-Segmented Negative-Sense RNA Viruses.

Authors:  Srirupa Chatterjee; Christopher F Basler; Gaya K Amarasinghe; Daisy W Leung
Journal:  J Mol Biol       Date:  2016-07-31       Impact factor: 5.469

Review 3.  Mechanisms of Non-segmented Negative Sense RNA Viral Antagonism of Host RIG-I-Like Receptors.

Authors:  Daisy W Leung
Journal:  J Mol Biol       Date:  2019-06-14       Impact factor: 5.469

4.  Crystal Structure of the Marburg Virus VP35 Oligomerization Domain.

Authors:  Jessica F Bruhn; Robert N Kirchdoerfer; Sarah M Urata; Sheng Li; Ian J Tickle; Gérard Bricogne; Erica Ollmann Saphire
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

5.  Effects of Filovirus Interferon Antagonists on Responses of Human Monocyte-Derived Dendritic Cells to RNA Virus Infection.

Authors:  Benjamin C Yen; Christopher F Basler
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

6.  Crystal Structure of the Marburg Virus Nucleoprotein Core Domain Chaperoned by a VP35 Peptide Reveals a Conserved Drug Target for Filovirus.

Authors:  Tengfei Zhu; Hao Song; Ruchao Peng; Yi Shi; Jianxun Qi; George F Gao
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

Review 7.  Molecular pathogenesis of viral hemorrhagic fever.

Authors:  Christopher F Basler
Journal:  Semin Immunopathol       Date:  2017-05-29       Impact factor: 9.623

8.  Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways.

Authors:  Caroline G Williams; Joyce Sweeney Gibbons; Timothy R Keiffer; Priya Luthra; Megan R Edwards; Christopher F Basler
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

Review 9.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

10.  Ebola Virus Shed Glycoprotein Triggers Differentiation, Infection, and Death of Monocytes Through Toll-Like Receptor 4 Activation.

Authors:  Mathieu Iampietro; Rodrigo I Santos; Ndongala Michel Lubaki; Alexander Bukreyev
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.